[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Lin TL, Shih LY, Hung YS, Kuo TT: Thymic hyperplasia following successful chemotherapy for Hodgkin's lymphoma: report of a case. Chang Gung Med J; 2009 Jan-Feb;32(1):98-103
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for thymic hyperplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic hyperplasia following successful chemotherapy for Hodgkin's lymphoma: report of a case.
  • A recurrent mediastinal mass in a patient following treatment for Hodgkin's lymphoma presents a diagnostic challenge.
  • We report a 17-year-old boy with nodular sclerosing Hodgkin's lymphoma, stage IIIsA, who achieved complete response after 6-cycle chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine and developed thymic hyperplasia 6 months later.
  • Most patients were young, had the nodular sclerosis subtype of Hodgkin's lymphoma, were in an advanced stage, and had a latency of 2 to 12 months following successful chemotherapy.
  • Resection of the tumor for tissue diagnosis is mandatory to establish an accurate diagnosis and thus avoid further harmful therapy.
  • [MeSH-major] Hodgkin Disease / drug therapy. Thymus Gland / pathology

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292945.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 19
  •  go-up   go-down


2. Iyengar P, Mazloom A, Shihadeh F, Berjawi G, Dabaja B: Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes. Cancer; 2010 Aug 15;116(16):3825-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes.
  • BACKGROUND: Most Hodgkin lymphoma (HL) patients present with disease in nodal regions.
  • However, in a small subset, disease develops in unique anatomic sites such as the head and neck area.
  • They reviewed the records for site of involvement, pathology, treatment, and survival.
  • Specifically, 10 of 34 patients had disease in the tonsils, 9 in the nasopharynx, 8 in the thyroid, 3 in the parotid, 2 in the adenoids, and 1 each in Waldeyer's ring and nasal antrum.
  • Median age at diagnosis was 31.5 years, average age at diagnosis was 38 years, and 22 of 34 were male; 23 had stage I or II disease.
  • Pathologically, 14 of 34 had the nodular sclerosis subtype, whereas 15 had mixed cellularity.
  • Twenty-nine of 34 had nodal neck disease at presentation.
  • Five of 34 received chemotherapy alone, 5 received radiation alone, and 24 received combination therapy.
  • The most commonly used chemotherapy regimens were ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and MOPP (mechlorethamine, vincristine, procarbazine, and prednisone).
  • At last follow-up, 85% were disease-free.
  • CONCLUSIONS: HL of the head and neck is primarily diagnosed as early stage disease of men and of young to middle-aged individuals.
  • Chemotherapy and primary/adjuvant radiotherapy offer excellent local and systemic control.
  • The extent to which nodal disease is present in the neck does not alter outcomes when combined modality therapy is offered.
  • Despite the unique anatomic location of these lesions, standard HL protocols work effectively to promote disease-free survival.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564093.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H, GESIDA Group, GELCAB Group: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):191-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Although doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is considered the standard chemotherapy regimen for Hodgkin's lymphoma (HL), information on the results of this therapy in human immunodeficiency (HIV)-related HL is scarce.
  • We analyzed the results of the ABVD regimen and highly active antiretroviral therapy (HAART) in patients with advanced stage, HIV-related HL.
  • Response to chemotherapy, overall survival (OS) and event-free survival (EFS) were recorded.
  • The histologic subtype of HL was nodular sclerosis in 17 patients (27%), mixed cellularity in 25 (41%), lymphocyte depletion in 10 (16%) and non-specified in the remaining 10 (16%).
  • Twenty-one (34%) patients were in stage III and 41 (66%) in stage IV.
  • INTERPRETATION AND CONCLUSIONS: In patients with advanced stage, HIV-related HL, treatment with ABVD together with HAART is feasible and effective.
  • This supports the concept that patients with HIV-related HL should be treated in the same way as immunocompetent patients if HAART, adequate supportive therapy and anti-infectious prophylaxis are given concomitantly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Hodgkin Disease / virology. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4-Positive T-Lymphocytes / metabolism. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296568.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


Advertisement
4. Gopal AK, Metcalfe TL, Gooley TA, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG, Press OW: High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer; 2008 Sep 15;113(6):1344-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
  • BACKGROUND: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease.
  • We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients.
  • Baseline characteristics included median age = 35 years (range, 14-59 years), stage III/IV = 49 (77%), nodular sclerosis histology = 51 (80%), and prior radiation = 32 (50%).
  • Twenty-six patients (41%) received total body irradiation (TBI)-based regimens, and 38 (59%) underwent non-TBI conditioning.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:67-71 [2049322.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):139-43 [6174060.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1381-90 [7858268.001]
  • [Cites] Nouv Rev Fr Hematol. 1994 Dec;36(6):423-30 [7753613.001]
  • [Cites] Blood. 1997 Feb 1;89(3):801-13 [9028311.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):745-52 [9384476.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):289-95 [9602263.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):461-7 [15534357.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):625-33 [15737986.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] Lancet. 2005 Jun 4-10;365(9475):1934-41 [15936420.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4669-78 [16034043.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2896-902 [16002426.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83 [16443515.001]
  • [Cites] Blood. 2006 Jul 15;108(2):705-10 [16551968.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(3):211-6 [16770314.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1485-8 [10643540.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):665-72 [10942053.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1395-404 [11230484.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):54-9 [15124135.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1222-30 [15277262.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):210-8 [1732422.001]
  • (PMID = 18623377.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA044991-21; United States / NCI NIH HHS / CA / K08 CA095448; United States / NCI NIH HHS / CA / CA095448-05; United States / NCI NIH HHS / CA / K08 CA095448-05; United States / NCI NIH HHS / CA / K23 CA085479; United States / NCI NIH HHS / CA / P01 CA044991; United States / NCI NIH HHS / CA / K23CA85479; United States / NCI NIH HHS / CA / K23 CA085479-06; United States / NCI NIH HHS / CA / P01CA44991; United States / NCI NIH HHS / CA / K08CA095448; United States / NCI NIH HHS / CA / CA085479-06; United States / NCI NIH HHS / CA / CA044991-21
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS115907; NLM/ PMC2700660
  •  go-up   go-down


5. Yahalom J: Favorable early-stage Hodgkin lymphoma. J Natl Compr Canc Netw; 2006 Mar;4(3):233-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable early-stage Hodgkin lymphoma.
  • The category of favorable early-stage Hodgkin lymphoma (HL) includes patients with Ann Arbor stages I or II disease with no bulky disease or B symptoms.
  • The precise definition of favorable versus unfavorable early-stage disease may vary among American and European cooperative groups.
  • The overall 10-year survival rate of patients with favorable early-stage HL exceeds 90%.
  • Indeed, effective treatments for this group of patients have been available for more than 4 decades.
  • However, treatment strategies have radically changed over the past 15 years and focus now on maintaining the high cure rate while reducing the risk of treatment-related long-term morbidity.
  • The optimal treatment is still evolving, and more recently, reduction in the total amount of chemotherapy and in radiation field and dose has shown excellent results.
  • Combined modality therapy is the preferred treatment for patients with classical favorable early-stage HL (nodular sclerosis or mixed cellularity histology).
  • Patients with early-stage lymphocyte predominance HL are highly curable using involved-field radiation therapy (IFRT) alone and do not require chemotherapy.
  • Classical favorable HL is also curable with radiotherapy alone or with chemotherapy alone, but larger fields and higher-dose radiation or longer chemotherapy is required compared with combined modality.
  • The freedom from treatment failure rate is significantly better with a combination of short chemotherapy and IFRT than with either chemotherapy or radiotherapy alone.
  • Although combined modality is the standard preferred treatment for favorable disease, radiation therapy alone or chemotherapy alone could be considered under special circumstances or as part of an investigational protocol.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Staging. Radiotherapy. Survival Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507270.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


6. Sagan D, Semczuk A, Lampka E: Combination chemotherapy for Hodgkin's lymphoma during pregnancy: favorable outcome for mother and child. J Obstet Gynaecol Res; 2010 Aug;36(4):882-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy for Hodgkin's lymphoma during pregnancy: favorable outcome for mother and child.
  • The management of such cases poses unusual medical and ethical challenges, particularly in hematological malignancies, when potentially teratogenic chemotherapy is indicated.
  • We report a case of stage IIA nodular sclerosis Hodgkin's lymphoma (HL), diagnosed in a 24-year-old woman at 18 weeks of gestation.
  • Individualized combination chemotherapy according to etoposide-vinblastine-doxorubicin (EVA) regimen was administered, resulting in effective local control of the disease and improvement in the patient's general condition.
  • Four weeks later, bleomycin-dacarbazine-doxorubicin-vinblastine (ABVD) chemotherapy was commenced, which provided complete remission after five cycles.
  • Individualized chemotherapy for HL according to EVA regimen during the second and third trimesters of pregnancy, with early cesarian delivery, followed by ABVD regimen, provided a positive outcome both for the mother and her child.
  • This strategy may be considered as an alternative for the treatment of HL in pregnancy, and deserves further clinical assessment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Bleomycin. Dacarbazine. Disease-Free Survival. Doxorubicin. Etoposide. Female. Humans. Pregnancy. Treatment Outcome. Vinblastine

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666963.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol; EVA regimen
  •  go-up   go-down


7. Provencio M, España P, Millán I, Sánchez A, Cantos B, Bonilla F: The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone. Leuk Lymphoma; 2003 Feb;44(2):263-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone.
  • The treatment of choice for patients with early stage Hodgkin's disease (HD) has been extended field or subtotal nodal irradiation.
  • Remission rates of over 95% have been obtained, however, about 5% of stage I and II patients will suffer from progressive disease while on therapy and an additional 15-20% will relapse.
  • Chemotherapy (Ch) alone has not been adequately tested in early-stage HD.
  • In this study, all HD stage I and II patients treated with Ch alone in the University Hospital "Clínica Puerta de Hierro" between 1980 and 1997 were reviewed.
  • Three (8.5%) patients died: two due to a second tumour (non-Hodgkin's lymphoma and myeloid acute leukaemia) and the other due to sepsis post-Ch.
  • Univariate and multivariate analysis only associated histology subtype relative risk (RR) 4.0 nodular sclerosis (95% IC, 1.0-5.5; p:0.02) with higher relapse.
  • In conclusion, we believe that death from HD in early-stage patients is unusual and mortality from causes other than HD occurs many years later.
  • Outside clinical trials due to the lack of clear prognostic factors, with the exception of specific situations, patients should be informed of all the possible alternatives as well as the consequences of the treatments employed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Disease Management. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12688343.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Olivares Camacho JL, Cabrera V, Cabrera JI: [Hodgkin's lymphoma with thoracic column metastasis. A case report]. Acta Ortop Mex; 2008 Jan-Feb;22(1):62-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma with thoracic column metastasis. A case report].
  • [Transliterated title] Linfoma de Hodgkin con metástasis a columna torácica. Presentación de caso.
  • This 20 years old male patient with a history of Hodgkin's disease since 1996, stage II variety nodular sclerosis, was initially managed with radiotherapy and chemotherapy ending such treatment in January 1997, subsequently treated with interferon for one year, ending in January 1998, presented complete remission and was maintained in observation; in June 1999 started with thoracolumbar pain, weakness and diminished sensitivity on lower limbs, studies were conducted and diagnosed epidural tumor from levels T9 to T12, with important spinal cord compression; the patient was submitted to surgery and neurological recovery was complete.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / surgery. Spinal Neoplasms / secondary. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672756.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


9. Ansell SM, Armitage JO: Management of Hodgkin lymphoma. Mayo Clin Proc; 2006 Mar;81(3):419-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Hodgkin lymphoma.
  • Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the United States.
  • The disease is composed of 2 distinct entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL.
  • Classical HL includes the subgroups nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich.
  • Selection of the appropriate therapy Is based on accurately assessing the stage of disease.
  • Patients with early-stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by Involved-field radiation therapy, whereas those with advanced-stage disease receive a longer course of chemotherapy without radiation therapy.
  • Although many patients respond well to initial therapies and have durable long-term remissions, a subset of patients has resistant disease and experiences relapse even after subsequent high-dose chemotherapy and autologous stem cell transplantation.
  • New therapies are clearly needed for these patients.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. Salvage Therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529147.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


10. Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ: [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):630-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
  • OBJECTIVE: To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).
  • METHODS: From 1999 to 2002, totally 150 patients with stage I or II HL were treated in our hospital.
  • They were stratified into several groups based on initial treatment strategy: chemotherapy alone (CT group, n = 22), radiotherapy alone (RT group, n = 18), combined-modality therapy (CMT group, n = 109) and surgical resection (SR group, n = 1).
  • Chemotherapy regimens were mainly ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) and MOPP (mechlorethamine, vincristine, procarbazine and prednisone).
  • RESULTS: The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1).
  • There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy.
  • The overall 7-yr survival rate was 89.3%, and treatment failure rate at 6 years was 18.8%.
  • The response rate of CMT group was superior to that of CT group, and the patients with nodular sclerosis or mixed-cellularity type had significantly lower risk of treatment failure (P = 0.009 and 0.019, respectively).
  • The multivariate analysis revealed that the treatment strategies affected the prognosis significantly.
  • The risk of failure of chemotherapy alone was 2.52 times higher than that of combined-modality therapy (P = 0.004).
  • CONCLUSION: Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma.
  • Though its acute adverse effects are more severe than that of chemotherapy or radiotherapy alone, it may reduce the risk of treatment failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use. Young Adult


11. Móciková H, Konífrová E, Stríteský J: [Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. Cas Lek Cesk; 2009;148(9):434-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis].
  • [Transliterated title] Závazná kozní toxicita po lécbe ifosfamidem, gemcitabinem a vinorelbinem u pacienta s relapsem Hodgkinova lymfomu a ichtyózou.
  • Nodular sclerosis classical Hodgkin lymphoma, clinical stage IIB with cervical and axillar lymph node involvement was histologically proven in a 47-year-old male patient with a long-lasting history of ichthyosis.
  • Patient was treated with six cycles of combined chemotherapy: doxorubicin, bleomycin, vinblastine and dacarbazine.
  • 15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging.
  • Patient was successfully treated with six cycles of chemotherapy: ifosfamide, carboplatinum and etoposide followed by radiotherapy.
  • 4 years after previous therapy the second relapse of Hodgkin lymphoma occurred with axillar and inguinal lymph node involvement.
  • Patient was treated with three cycles of combined chemotherapy: ifosfamide, gemcitabine, vinorelbine and prednisone.
  • This chemotherapy caused neutropenia WHO grade 4 after each cycle and a serious diffuse toxoallergic cutaneous reaction with bullous erythema developed.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Hodgkin Disease / drug therapy. Ichthyosis / complications. Ifosfamide / adverse effects. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Ichthyosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899733.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Harris MA, Radford JA, Deakin DP, James RD, Swindell R, Cowan RA: Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):53-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
  • AIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma.
  • Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy.
  • Fifteen of the 33 patients were stage IA, 15 were IIA, 1 was IB and 2 were IIB.
  • Histological subtype was lymphocyte predominant (15/33), nodular sclerosis (11/33), mixed cellularity (4/33), lymphocyte-rich classical (1/33) and unclassifiable (2/33).
  • The median time to relapse was 37 months (range 7-65 months).
  • All five relapses had received radiotherapy alone and four were salvaged with chemotherapy.
  • There have been four second malignancies and one patient transformed to high-grade non-Hodgkin's lymphoma.
  • No patient has died of Hodgkin's lymphoma.
  • CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease.
  • The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Chlorambucil / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768756.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ChlVPP-EVA regimen; VAPEC-B protocol
  •  go-up   go-down


13. Ngeow JY, Quek R, Tao M, Tan HC, Lim L, Tan I, Kaneswaran R, Lim ST: Analysis of long-term treatment outcomes and toxicty of HL. J Clin Oncol; 2009 May 20;27(15_suppl):e19536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term treatment outcomes and toxicty of HL.
  • : e19536 Background: Prognosis of patients with Hodgkin lymphoma (HL) has substantially improved but therapy of HL can however contribute to delayed toxicity.
  • Long term treatment outcomes of HL in our local population were evaluated.
  • METHODS: Clinical and treatment data was prospectively collected from all patients with a histological diagnosis of HL.
  • Patients who were young (< 30 years) were more likely to present with nodular sclerosis HL (p=0.0001).
  • Treatment outcomes were comparable to other published series, 85% of cases received ABVD based treatment.
  • 5 year OS for early stage HL was 92% and 88% for advanced stage HL.
  • Of note, comparing patients with early stage (Stage I/ II) HL (n=114) who had ABVD 4 cycles followed by involved field radiotherapy (IFRT) with those who received 6-8 cycles of ABVD, there was no difference in OS, FFTF (p= 0.99, 0.48 respectively).
  • Bulky early stage HL who received 6 cycles of ABVD and IFRT had better FFTF rates than those who had just 4 cycles of ABVD followed by IFRT (p=0.06).
  • In contrast, patients patients with advanced HL (Stage III/ IV) (n=70) who completed 6-8 cycles of ABVD did not benefit from additional IFRT even in the presence of bulky disease (n=15).
  • Neither the omission of bleomycin nor the presence BIP adversely affected treatment outcomes.
  • 1) Epidemiology of HL in Singapore is increasingly similar to that of developed countries with a peak in young adults.
  • 2)Young age was predictive of a nodular sclerosis subtype 3) Abbreviated chemotherapy using 4 cycles of ABVD followed by IFRT performed similarly to 6 cycles of ABVD in early stage HL, but in patients with bulky disease this may not be sufficient.
  • BIP and the omission of bleomycin did not adversely affect treatment outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Dunleavy KM, Butrynski J, Steinberg S, Grant N, White T, Jaffe ES, Wilson WH: Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL). A report on toxicity, efficacy and prognostic indicators of outcome. J Clin Oncol; 2004 Jul 15;22(14_suppl):6598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL). A report on toxicity, efficacy and prognostic indicators of outcome.
  • : 6598 Background: In relapsed/refractory HL, an effective and well tolerated salvage regimen has important roles both prior to autologous stem cell transplant (SCT) and as palliative therapy in patients (pts) who are ineligible for or have failed SCT.
  • Pts received fixed dose EPOCH chemotherapy (etoposide 200 mg/m<sup>2</sup>, vincristine 1.6 mg/m<sup>2</sup> (no cap) and doxorubicin 40 mg/m<sup>2</sup> CIVI x 96-hrs D1-4; cyclophosphamide 750 mg/m<sup>2</sup> IV D5 and prednisone 60 mg/m<sup>2</sup> qd D1-6 ) with G-CSF q21 days until disease progression or stabilization over ≥ 2 cycles.
  • RESULTS: Of 54 pts, median (range) age was 31 yrs (19-64), 35 (66%) were male, stage was III in 11(21%) and IV in 30(56%), and 29 (55%) had B symptoms.
  • Histology included nodular sclerosis 34 (64%), mixed cellularity 3 (25%), and lymphocyte depleted 5 (9%) classical HL, and nodular lymphocyte predominant HL 1 (2%).
  • 24 (45%) pts had had ≥ 2 prior regimens, 27 (51%) pts received chemotherapy within the previous 10 mos, and 40 (75%) pts had responded to their last treatment.
  • There was one treatment related death.
  • 45 (84%) pts responded with 23 (44%) CR and 21 (40%) PR.
  • With a median follow-up of 68 mos, the median progression-free (PFS) and overall survivals (OS) are 10 and 40 mos, and at 68 mos median follow-up, PFS and OS are 21% and 41%.
  • Multivariate analysis revealed that the no. of prior drugs and response to the preceding regimen significantly influenced OS and PFS; in addition PFS was significantly influenced by performance status and mos since previous chemotherapy.
  • It should be considered as salvage therapy prior to SCT or for palliation in incurable HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016222.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, d'Amore F: Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma.
  • : 8528 Background: Classical Hodgkin lymphoma (cHL) is characterized by a minority of neoplastic cells surrounded by a heterogeneous background of non-neoplastic cells.
  • METHODS: A tissue microarray (TMA) was constructed with paraffin embedded tissue specimens from 286 cHL cases.
  • Clinical data were obtained from the Danish population-based lymphoma registry and clinical records.
  • All pts were homogeneously treated with either chemo-radiotherapy (localised disease) or ABVD chemotherapy (advanced disease).
  • The histological subtypes were: nodular sclerosis (NS)-type I, 167 cases (59 %); NS-type II, 71 (25%); mixed cellularity (MC), 44 (15 %); lymphocyte-rich, lymphocyte-depleted and cHL-NOS, each one case.
  • A high number of tumour-infiltrating CD163+ cells was associated with a significantly poorer overall and event-free survival (p=0.029 and p=0.018, respectively).
  • Furthermore, a high expression of CD163 strongly correlated to stage IV disease (p=0.035), presence of B-symptoms (p=0.008), lymphocytopenia (p=0.003), hypersedimentation (p=0.009).
  • CONCLUSIONS: In cHL, a high number of intratumoral CD163+ monocytes/macrophages correlates with adverse outcome and with clinical parameters reflecting underlying aggressive disease biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960903.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C, Pangalis GA: Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol; 2001 Nov-Dec;67(5-6):279-88
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.
  • BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional chemotherapy in 60--70% of patients.
  • The pretreatment identification of a sizeable subgroup of patients with sufficiently low failure-free survival (FFS) to be eligible for investigational treatment is necessary.
  • METHODS: A retrospective review of patients with advanced HL, defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with anthracycline-based regimens.
  • RESULTS: We identified 277 patients with a median age of 32 yr (14--78), 57% of whom were males.
  • Most patients had nodular sclerosis (64%) and mixed cellularity (26%) histology.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872075.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


17. Bień E, Stachowicz-Stencel T, Zawitkowska-Klaczyńska J, Adamkiewicz-Drozyńska E, Odój T, Połczyńska K, Mitura-Lesiuk M, Stefanowicz J, Sierota D, Szołkiewicz A, Birkholz D, Hennig M, Kowalczyk JR, Balcerska A: [Clinical characteristics and therapy outcome in children with stage IV Hodgkin's lymphoma--the experience of two oncological centres]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):631-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and therapy outcome in children with stage IV Hodgkin's lymphoma--the experience of two oncological centres].
  • [Transliterated title] Charakterystyka kliniczna i wyniki leczenia dzieci z choroba Hodgkina w IV stadium zaawansowania--doświadczenia dwóch ośrodków onkologicznych.
  • The cure rate in children with Hodgkin's disease (HD), at present time exceeds 90% but the prognosis in stage IV HD is much worse.
  • THE AIM of the study was to analyze the initial symptoms, course and results of oncological therapy in children with stage IV of Hodgkin's disease.
  • MATERIAL AND METHODS: The analyzed group comprised of 15 patients with IV stage HD (M/F: 11/4, mean age: 12 years), treated from January 1993 to March 2005, in two Polish centres of paediatric oncology in Gdansk and Lublin.
  • The diagnosis and therapy were carried out according to the current protocols approved by the Polish Paediatric Leukaemia / Lymphoma Study Group (PPGBCh).
  • The nodular sclerosis histopathological type of HD predominated.
  • Poor response to standard treatment was observed in five children.
  • One patient received additional cycles of chemotherapy MVPP/B-DOPA, four children were administered the 2nd line chemotherapy Salvage 95.
  • One boy with very poor response to the 1st and 2nd therapy lines additionally underwent megachemotherapy with peripheral blood stem cells transplantation.
  • 13 out of 15 children are alive and free of disease with mean follow-up duration of 6 years.
  • CONCLUSION: Chemo- and radiotherapy implemented according to protocols approved by the PPGBCh for children with stage IV HD, result in complete remission in most patients.
  • Diagnosis made at earlier stages would result in giving less aggressive therapy, connected with a lower risk of durable late complications.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy
  • [MeSH-minor] Academic Medical Centers. Adolescent. Chemotherapy, Adjuvant. Child. Child Health Services. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Poland. Radiotherapy, Adjuvant. Recurrence. Severity of Illness Index. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317894.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


18. Büyükpamukçu M, Varan A, Akyüz C, Atahan L, Ozyar E, Kale G, Köksal Y, Kutluk T: The treatment of childhood Hodgkin lymphoma: improved survival in a developing country. Acta Oncol; 2009;48(1):44-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
  • BACKGROUND: To evaluate the clinical characteristics, treatment regimens, and outcome of children with Hodgkin lymphoma in a developing country over a period of 34 years.
  • METHODS: This paper retrospectively evaluates the treatment and prognosis of 614 children with Hodgkin lymphoma disease between 1971 and 2005.
  • All patients were treated with chemotherapy, and also received radiotherapy.
  • RESULTS: There were 452 males and 162 females with a median age of 8 years (2 to 21); 183 patients had B symptoms.
  • There were 165, 185, 145, and 119 patients in stage I, II, III, and IV, respectively.
  • Histopathologic subtypes were mixed cellularity (344 patients), nodular sclerosis (90), lymphocytic predominance (62), lymphocytic depletion (46), unclassified types (69), and nodular lymphocyte predominant Hodgkin lymphoma (3).
  • Overall (OS) and event-free survival (EFS) rates were 83 and 60%, though OS rates varied according to chemotherapy protocol; age; presence of B symptoms, leukocytosis, anemia, and extranodal involvement; and stage at diagnosis.
  • Over the years, the median age of patients increased, as did the frequency of the nodular sclerosing type of disease.
  • The increase in the median age and in the frequency of the nodular-sclerosing type are thought to be related to the development status of Turkey.
  • The ABVD protocol yielded the best survival rates and should be used for treatment of patients with Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Male. Multivariate Analysis. Neoplasm Staging. Survival Rate. Treatment Outcome. Turkey / epidemiology. Young Adult


19. Molin D: Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci; 2004;109(3):179-228
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.
  • Hodgkin lymphoma (HL) is characterised histologically by a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells surrounded by benign cells, and clinically by a relatively good prognosis.
  • The treatment, however, leads to a risk of serious side effects.
  • Knowledge about the biology of the disease, particularly the interaction between the HRS cells and the surrounding cells, is essential in order to improve diagnosis and treatment.
  • It correlated to number of tumour eosinophils, nodular sclerosis (NS) histology, and the negative prognostic factors high erythrocyte sedimentation rate (ESR) and blood leukocyte count (WBC).
  • Survival in patients with early and intermediate stage HL, diagnosed between 1985 and 1992, was generally favourable and comparatively limited treatment was sufficient to produce acceptable results for most stages.
  • Patients treated with a short course of chemotherapy and radiotherapy had an excellent outcome.
  • [MeSH-major] Bystander Effect / physiology. Eosinophils / metabolism. Hodgkin Disease / diagnosis. Mast Cells / metabolism


20. Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL: HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol; 2004 May;121(5):727-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases.
  • We retrospectively analyzed 45 cases of HIV-associated Hodgkin lymphoma (HIV-HL).
  • HIV-HL generally is a disease of young white men (mean age, 40.1 years) who acquired HIV infection by homosexual or bisexual behavior (68%), intravenous drug use (24%), and/or blood transfusion (8%).
  • Morphologic classification of nodal biopsy specimens (2001 World Health Organization criteria) included 15 mixed cellularity Hodgkin lymphomas (MCHLs), 14 nodular sclerosis Hodgkin lymphomas (NSHLs), 9 lymphocyte depleted Hodgkin lymphomas (LDHLs), and 7 classic Hodgkin lymphomas, type not further categorized.
  • The Hodgkin-Reed-Sternberg (HRS) cells expressed positive immunoreactivity with fascin (30/30 [100%]), CD30 (35/37 [95%]), CD15 (32/36 [89%]), bcl-X(L) (25/31 [81%]), bcl-2 (15/29 [52%]), CD20 (4/34 [12%]), bcl-6 (3/28 [11%]), and Epstein-Barr virus latent membrane protein-1 (32/33 [97%]) and were nonreactive for CD138/syndecan-1.
  • At diagnosis, most patients (n = 27) had high-stage disease (IV(E)) associated with an aggressive course (16% 5-year survival).
  • LDHL behaved more aggressively than MCHL and NSHL (15% vs 40%, 5-year survival, respectively), as did disease with a sarcomatoid pattern (11% 5-year survival).
  • Chemotherapy and radiotherapy proved efficacious in a minority of these patients.
  • [MeSH-major] HIV Infections / pathology. Hodgkin Disease / pathology. Lymphoma, AIDS-Related / pathology


21. Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M: Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol; 2010 Apr;91(3):446-55
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.
  • The Japan Clinical Oncology Group conducted two multicenter phase II trials in 200 patients with advanced Hodgkin lymphoma (HL) in the 1990s.
  • Five-year overall survival (OS) among these 167 patients was 88.3%, including 89.2% among nodular sclerosis and 82.2% among mixed cellularity cases.
  • Seven unfavorable prognostic factors for OS on univariate analysis were male, B symptoms, clinical stage of III or IV, elevated serum LDH, elevated alkaline phosphatase, elevated beta2-microglobulin, and pathological subtype (mixed cellularity and lymphocyte depletion).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase II as Topic / statistics & numerical data. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Models, Statistical
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / mortality. Lymphoma, Large-Cell, Anaplastic / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Multivariate Analysis. Prognosis. Radiotherapy / statistics & numerical data. Remission Induction. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(6):473-6 [7554038.001]
  • [Cites] Int J Hematol. 2004 Nov;80(4):341-50 [15615259.001]
  • [Cites] J Natl Cancer Inst. 2009 Jul 1;101(13):928-37 [19535773.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1227-31 [8260377.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):233-44, vi [18395147.001]
  • [Cites] J Clin Epidemiol. 2004 Nov;57(11):1138-46 [15567629.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1405-11 [11142480.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):352-60 [16770772.001]
  • [Cites] Haematologica. 2002 Jul;87(7):701-8; discussion 708 [12091120.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1108-11 [8501496.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8003-11 [16204002.001]
  • [Cites] Eur J Haematol. 2001 Nov-Dec;67(5-6):279-88 [11872075.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4626-33 [16954517.001]
  • [Cites] Ann Intern Med. 1991 May 15;114(10):855-60 [2014946.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1749-60 [16984979.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1518-27 [2674337.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):24-40 [19087093.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):215-8 [16449681.001]
  • [Cites] Stat Med. 2000 Feb 29;19(4):453-73 [10694730.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2534-8 [12467067.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1173-86 [1694235.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:67-74 [12078906.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Sep;5(9):543-56 [18679394.001]
  • [Cites] BMJ. 2009 Mar 31;338:b604 [19336487.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Sep;71(3):222-32 [19179093.001]
  • (PMID = 20198461.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Nicolatou-Galitis O, Papadaki T, Moschovi M, Kamma JJ, van Vliet-Constantinidou C, Tsoumakas C, Kattamis A, Tzortzatou-Stathopoulou F: Gingival overgrowth as the initial paraneoplastic manifestation of Hodgkin's lymphoma in a child. A case report. J Periodontol; 2001 Jan;72(1):107-12
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival overgrowth as the initial paraneoplastic manifestation of Hodgkin's lymphoma in a child. A case report.
  • BACKGROUND: The purpose of this paper is to present the first case of gingival overgrowth, premature root resorption, and alveolar bone loss, which preceded the diagnosis of a stage IVB Hodgkin's lymphoma (HL) in a 9-year-old boy.
  • RESULTS: Histological examination of both gingival biopsies disclosed a mixed inflammatory infiltrate, while classical Hodgkin's lymphoma of the nodular sclerosis type was diagnosed from the second lymph node biopsy.
  • Chemotherapy was instituted with mustard-vincristine-procarbazine-prednizone and adriamycine-bleomycine-vinblastine-dacarbazine.
  • Remission of the lymphoma was observed with concomitant regression of the gingival overgrowth.
  • CONCLUSIONS: The inflammatory gingival overgrowth, premature root resorption of deciduous teeth, and alveolar bone loss in this case, in conjunction with the regression of gingival overgrowth which followed the completion of chemotherapy, are strongly indicative of a paraneoplastic manifestation of HL.
  • [MeSH-major] Gingival Overgrowth / etiology. Hodgkin Disease / complications. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Alveolar Bone Loss / etiology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Gingival Hyperplasia / etiology. Humans. Lymph Nodes / pathology. Male. Mechlorethamine / administration & dosage. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Root Resorption / etiology. Tooth, Deciduous / pathology. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Periodontol. 2010 Apr;81(4):641. Moshovi, M [corrected to Moschovi, M]
  • (PMID = 11210066.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


23. Niitsu N, Okamoto M, Tomita N, Aoki S, Tamaru J, Miura I, Hirano M: Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1908-14
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
  • A German Hodgkin's lymphoma (HL) study group designed the BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) regimen.
  • In the BEACOPP regimen, treatment intervals were shortened and the dose-intensity was increased compared with those in the ABVD regimen (doxorubicin, bleomycin, vinblastine and darcarbacine), resulting in a long-term disease-free survival rate of approximately 75-80%.
  • Between April 2001 and February 2004, 20 patients with HL of stage IIB or higher who had received no previous treatment were enrolled.
  • The histologic types were mixed cellularity in four cases and nodular sclerosis in 16 cases.
  • The stages were stage IIB in four cases, stage III in 12 cases, and stage IV in four cases.
  • Adverse drug reactions were grade 4 neutropenia in 12 patients, grade 3-4 thrombocytopenia in seven patients, and grade 3 or higher non-hematologic toxicities in two patients (stomatitis in one patient and ALT/AST elevation in one patient).
  • The BEACOPP regimen for advanced-stage HL showed an excellent complete remission rate and high efficacy even in stage III/IV patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Procarbazine / therapeutic use. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol
  •  go-up   go-down


24. Wang SA, Rahemtullah A, Faquin WC, Roepke J, Harris NL, Hasserjian RP: Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol; 2005 Dec;18(12):1577-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature.
  • Hodgkin's lymphoma rarely involves the thyroid gland.
  • We report the clinical and pathologic features of five cases of Hodgkin's lymphoma that presented as thyroid lesions.
  • One patient had a remote history of Hodgkin's lymphoma.
  • Thyroid fine-needle aspiration was performed before thyroidectomy in all cases; three of these cases contained some atypical cells, raising the possibility of Hodgkin's lymphoma.
  • Histologically, all cases were classical Hodgkin's lymphoma, nodular sclerosis subtype.
  • The four patients with primary thyroid lymphoma had Stage IIE disease.
  • All patients were treated with surgical excision and chemotherapy, with or without radiation therapy, and were alive after 2 months to 7 years of follow-up.
  • A review of the English literature between 1962 and 2005 revealed 16 cases of thyroid Hodgkin's lymphoma, with a female preponderance and generally favorable outcome similar to the cases in our series.
  • Hodgkin's lymphoma of the thyroid is rare and can mimic a primary thyroid epithelial tumor or thyroiditis clinically.
  • Hodgkin's lymphoma should be considered in the differential diagnosis of thyroid neoplasms.
  • [MeSH-major] Hodgkin Disease / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Chronic Disease. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hypothyroidism. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Sclerosis / pathology. Thyroidectomy. Thyroiditis. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258502.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • There were 27 Stage IA and 67 Stage IIA patients.
  • All patients were treated to 3600 cGy with a 400 cGy boost to the involved field.
  • Nine of the relapses had nodular sclerosis histology, one had lymphocyte predominance, and none had mixed cellularity.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


26. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results. Ann Oncol; 2005 Dec;16(12):1936-40
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
  • BACKGROUND: Hodgkin's disease (HD) accounts for 7.5% of childhood malignancies in Iran.
  • In order to minimize chemotherapy toxicity and avoid eventual hospitalization and psychological and financial burdens we have applied since 1988, for the first time in Iran, a treatment regimen based on subsequently revised DAL-HD 85-90 and later GPOH-HD 95 protocols.
  • PATIENTS AND METHODS: During the period 1988-2004, 40 children with HD received DAL/GPOH-HD-adapted treatment; 25 males (62.5%) and 15 females (37.5%) (male/female ratio 1.7; age 4-14 years, mean 8.8).
  • Staging was as follows: stage I; seven (17.5%); II, 11 (27.5%); III, 11 (27.5%); and IV, 11 (27.5%).
  • Histopathology: 22 patients had mixed cellularity (MC; 55%), 13 nodular sclerosis (32.5%), four lymphocyte predominance (LP; 10%) and one patient lymphocyte depletion (2.5%).
  • Stage IA and IIA patients (n = 15) received either OPA x2 (vincristine, prednisolone, doxorubicin) or OPPA x2 or OPEA x2 (vincristine, prednisolone, procarbazine and doxorubicin), the latter receiving etoposide instead of procarbazine, and applied to males.
  • Twenty nine patients (72.5%) received radiotherapy (20-25 Gy); four to the involved field (stage I), 25 to the upper mantel (stage II and also III with either residual or mediastinal mass) and three additionally to spleen and para-aortic lymph nodes.
  • Eleven patients received only chemotherapy.
  • Relapse occurred in eight patients (20%); seven stage IV (MC) and one stage IA (LP) with progression to IIIB.
  • Salvage chemotherapy consisted of MOPP/ABVD hybrid; six patients achieved a second sustained remission and three patients died: two due to relapse and progressive disease and the third one in CR, owing to thrombocytopenic hemorrhage and foudroyant pneumonia.
  • Aside from minor acute toxicities, three patients demonstrated azoospermia at the age of 18 years and one of these patients suffered non-Hodgkin lymphoma as a second malignancy.
  • Both received appropriate treatment and are over 10 years in CR.
  • CONCLUSIONS: The DAL/GPOH-HD-based treatment approach proved to achieve long-term sustained cure even in children with advanced HD disease.
  • The essentially outpatient diagnosis and treatment modus did not compromise the disease outcome, and was well tolerated and accepted by the patients and their parents.
  • The employed drugs are easily available and affordable.
  • This treatment approach is suitable for ambulatory use in developing countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157620.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Perin T, Canzonieri V, Gloghini A, Volpe R, Scarabelli C, Carbone A: Primary Hodgkin's disease of the vagina. Leuk Lymphoma; 2000 Apr;37(3-4):451-5
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Hodgkin's disease of the vagina.
  • We describe a patient with primary Hodgkin's disease (HD) of the vagina presenting with stage IEB.
  • Based on morphological and immunophenotypic features, the HD was classified as nodular sclerosis subtype, "syncytial" variant.
  • The patient, a 64-year old woman, received chemotherapy followed by radiation therapy.
  • She is still disease-free 14 months after diagnosis.
  • [MeSH-major] Hodgkin Disease / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Sclerosis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10752999.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


28. Axdorph U, Porwit-Macdonald A, Sjøberg J, Grimfors G, Bjørkholm M: T-cell-rich B-cell lymphoma - diagnostic and therapeutic aspects. APMIS; 2002 May;110(5):379-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell-rich B-cell lymphoma - diagnostic and therapeutic aspects.
  • BACKGROUND: Morphologically, T-cell-rich B-cell lymphoma (TCRB-NHL) may be indistinguishable from Hodgkin's disease (HD).
  • RESULTS: Twelve cases of TCRB-NHL were initially subclassified as HD (lymphocyte predominance 5, nodular sclerosis 3, and mixed cellularity 4).
  • Of these 12 TCRB-NHL patients, 6 were given radiotherapy alone, 5 MOPP/ABVD or similar combination chemotherapy, and one patient combined modality treatment.
  • Male sex (p<0.05) and inguinal involvement (p<0.001) were significantly more frequent when TCRB-NHL patients receiving HD treatment (n=12) were compared with the remaining patients with confirmed (conf) HD, while no significant differences were seen with regard to stage, bone marrow infiltration, splenomegaly or cause-specific survival.
  • Lymphoma cells in three samples stained positively for LMP-1.
  • [MeSH-major] Hodgkin Disease / diagnosis. Immunophenotyping / methods. Lymphoma, B-Cell / diagnosis. Proteins. T-Lymphocytes / cytology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12076255.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM Domain Proteins; 0 / Membrane Proteins; 0 / PDLIM7 protein, human; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


29. Al-Shemmari SH, Al-Humood S, Ameen R, Kamlesh S, Nemec J, Varghese A: Hodgkin's disease: Kuwait experience. Med Princ Pract; 2004 Jul-Aug;13(4):201-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: Kuwait experience.
  • OBJECTIVE: To describe histologic subtypes, clinical presentation and treatment outcome of Hodgkin's lymphoma in Kuwait.
  • SUBJECTS AND METHOD: Patients older than 15 years, diagnosed with Hodgkin's lymphoma between 1980 and 1998, were included in this retrospective analysis.
  • Data were collected using a standardized form that included demographics, histologic subtypes, clinical presentation, stage, extranodal involvement, treatment modality and follow-up.
  • Dominant histologic subtypes were nodular sclerosis 65 (46.4%) and mixed cellularity 42 (30%).
  • Disease-free survival according to treatment groups were: radiotherapy alone 100%, chemotherapy alone 88%, and combined modality 65%.
  • The 5-year Kaplan-Meier estimates of overall disease-free survival was 84%.
  • CONCLUSION: In the cohort of 137 patients with Hodgkin's disease the treatment with combined radiotherapy and chemotherapy had a remarkable outcome.
  • However, evaluation of long-term treatment complications is needed.
  • [MeSH-major] Hodgkin Disease
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kuwait / epidemiology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15181324.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement